Related content

Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 714-718

Spandidos Publications

Access to resources Recommend Favorite

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Recommendations for the reporting of surgically resected specimens of colorectal carcinoma

By Jass Jeremy   O’Brien Michael   Riddell Robert   Snover Dale  

Virchows Archiv, Vol. 450, Iss. 1, 2007-01 ,pp. : 1-13

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage III cervical cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 4, 2014-01 ,pp. : 518-524

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin or irinotecanbased treatment

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 356-362

Spandidos Publications

Access to resources Recommend Favorite